Jul 13, 2025
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
Jun 01, 2025
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
May 28, 2025
CARsgen's Satri-cel Granted Priority Review by the NMPA
May 11, 2025
CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy
Mar 18, 2025
CARsgen Announced 2024 Annual Results
Jan 20, 2025
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
Dec 30, 2024
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
Nov 06, 2024
CARsgen® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress
Oct 31, 2024
CARsgen® U.S. Clinical Holds Lifted by FDA
Aug 29, 2024
CARsgen® Announces 2024 Interim Results
Jun 15, 2024
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024
Jun 04, 2024
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO
Apr 29, 2024
CARsgen Submitted Responses to FDA Observations
Mar 27, 2024
CARsgen Announced 2023 Annual Results
Mar 01, 2024
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
Jan 19, 2024
CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting
Jan 15, 2024
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage a hepatocellular carcinoma at high risk of recurrence after surgical resection